BR112018007765A2 - composições de pirimidina, composições ultrapuras e sais das mesmas, métodos de fabricação das mesmas e métodos de uso das mesmas para tratamento de doenças e condições mediadas por receptor h4 de histamina (h4) - Google Patents

composições de pirimidina, composições ultrapuras e sais das mesmas, métodos de fabricação das mesmas e métodos de uso das mesmas para tratamento de doenças e condições mediadas por receptor h4 de histamina (h4)

Info

Publication number
BR112018007765A2
BR112018007765A2 BR112018007765A BR112018007765A BR112018007765A2 BR 112018007765 A2 BR112018007765 A2 BR 112018007765A2 BR 112018007765 A BR112018007765 A BR 112018007765A BR 112018007765 A BR112018007765 A BR 112018007765A BR 112018007765 A2 BR112018007765 A2 BR 112018007765A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
ultrapure
manufacture
histamine
Prior art date
Application number
BR112018007765A
Other languages
English (en)
Portuguese (pt)
Inventor
Barker Helen
Yeadon Michael
Liu Wai
Zhu Zhijian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112018007765A2 publication Critical patent/BR112018007765A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018007765A 2015-10-26 2016-10-25 composições de pirimidina, composições ultrapuras e sais das mesmas, métodos de fabricação das mesmas e métodos de uso das mesmas para tratamento de doenças e condições mediadas por receptor h4 de histamina (h4) BR112018007765A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562246482P 2015-10-26 2015-10-26
US201662329091P 2016-04-28 2016-04-28
US201662359066P 2016-07-06 2016-07-06
PCT/EP2016/075708 WO2017072131A1 (en) 2015-10-26 2016-10-25 Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions

Publications (1)

Publication Number Publication Date
BR112018007765A2 true BR112018007765A2 (pt) 2018-10-23

Family

ID=57200025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007765A BR112018007765A2 (pt) 2015-10-26 2016-10-25 composições de pirimidina, composições ultrapuras e sais das mesmas, métodos de fabricação das mesmas e métodos de uso das mesmas para tratamento de doenças e condições mediadas por receptor h4 de histamina (h4)

Country Status (21)

Country Link
US (2) US20170158671A1 (https=)
EP (1) EP3368528A1 (https=)
JP (1) JP2018531288A (https=)
KR (1) KR20180067683A (https=)
CN (1) CN108602801A (https=)
AU (2) AU2016344627B9 (https=)
BR (1) BR112018007765A2 (https=)
CA (1) CA3001636A1 (https=)
CL (1) CL2018001092A1 (https=)
CO (1) CO2018004323A2 (https=)
EC (1) ECSP18038867A (https=)
HK (1) HK1252050A1 (https=)
IL (1) IL258813A (https=)
MX (1) MX2018005140A (https=)
PE (1) PE20181364A1 (https=)
PH (1) PH12018500822A1 (https=)
RU (1) RU2018119104A (https=)
SG (1) SG11201802676QA (https=)
TW (1) TW201729810A (https=)
WO (1) WO2017072131A1 (https=)
ZA (1) ZA201802183B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
RU2020111694A (ru) * 2017-10-09 2021-11-12 Тева Фармасьютикал Индастриз Лтд. Новые соли и твердые формы эсциталопрама
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
JP2024506384A (ja) 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
CA3231766A1 (en) 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methods of treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
EP1543011B1 (en) 2002-09-06 2006-05-03 Janssen Pharmaceutica N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
KR101235116B1 (ko) * 2005-10-17 2013-02-20 에스케이케미칼주식회사 광학활성 암로디핀 겐티세이트 염의 제조방법
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP2008127359A (ja) * 2006-11-22 2008-06-05 Kowa Co アトピー性皮膚炎の予防及び／又は治療剤
EP3378476A1 (en) * 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus

Also Published As

Publication number Publication date
AU2020200840A1 (en) 2020-02-27
CA3001636A1 (en) 2017-05-04
RU2018119104A (ru) 2019-11-28
CL2018001092A1 (es) 2018-08-10
SG11201802676QA (en) 2018-05-30
AU2016344627B2 (en) 2019-11-07
HK1252050A1 (zh) 2019-05-10
ZA201802183B (en) 2019-02-27
RU2018119104A3 (https=) 2020-02-19
WO2017072131A1 (en) 2017-05-04
PE20181364A1 (es) 2018-08-27
EP3368528A1 (en) 2018-09-05
KR20180067683A (ko) 2018-06-20
AU2016344627B9 (en) 2019-11-28
ECSP18038867A (es) 2018-05-31
MX2018005140A (es) 2018-05-07
CO2018004323A2 (es) 2018-07-19
CN108602801A (zh) 2018-09-28
AU2016344627A1 (en) 2018-05-10
JP2018531288A (ja) 2018-10-25
TW201729810A (zh) 2017-09-01
IL258813A (en) 2018-06-28
US20190135787A1 (en) 2019-05-09
PH12018500822A1 (en) 2018-10-01
US20170158671A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112018007765A2 (pt) composições de pirimidina, composições ultrapuras e sais das mesmas, métodos de fabricação das mesmas e métodos de uso das mesmas para tratamento de doenças e condições mediadas por receptor h4 de histamina (h4)
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CY1125935T1 (el) Κρυσταλλικη μορφη του υδρογονοθειϊκου (s)-n-(5- ((r)-2-(2,5-διφθοροφαινυλ)-πυρρολιδιν-1-υλ)- πυραζολο[1,5-α]πυριμιδιν-3-υλ)-3- υδροξυπυρρολιδιν-1-καρβοξαμιδιου
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
MX368464B (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
UY35369A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
MX361527B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
MX390503B (es) Compuesto de pirimidina fusionada o sal del mismo.
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
PH12017500215A1 (en) Protein kinase c inhibitors and methods of their use
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
CL2014002497A1 (es) Uso de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina o (2-((4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)amino)quinazolin-6-il)amino)-4-metil-4,5-dihidrooxazol-4-il)metanol para el tratamiento contra el cancer cerebral metastasico o local.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
BR112018074941A2 (pt) combinações farmacêuticas
BR112017028492A2 (pt) Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il)(5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona.
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
MX367707B (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
BR112018072887A2 (pt) método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto
WO2018156895A8 (en) Inhibitors of bruton's tyrosine kinase
AR106577A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sus sales, sus métodos de preparación y sus métodos de uso para el tratamiento de enfermedades y condiciones mediadas por el receptor de histamina h4 (h4)
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]

Free format text: ALTERACAO DE DADOS CADASTRAIS NO INID (54).